All In Biotech

Drug Trial Radar · NCT00405418

Lantus Versus Levemir Treat-To-Target

Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir.

Last checked: Nov 20, 2026Latest source record: Sep 15, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 973 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

973

Actual

Start

Nov 2006

Primary completion

Jun 2008

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 30, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective: To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c \< 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L) Secondary objectives: * To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c \< 7% and \< 6.5% at the end of the treatment period * To compare the changes in HbA1c and fasting plasma glucose (FPG) * To compare the evolution of blood glucose profiles * To compare the day to day FPG variability, the insulin doses * To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets * To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L) * To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL \[3.9 mmol/L\]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL * To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio * To assess the quality of life and treatment satisfaction

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin glargineDrug

    Subcutaneous injection, once a day in the evening

  • Insulin DetemirDrug

    Subcutaneous injection, twice a day at breakfast and before dinner

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c recordedTime frame: At baseline, week 12 and week 24
  2. Self-monitored fasting BG in both treatment arms and pre-dinner BG in detemir armTime frame: On the 4 consecutive days before each visit
  3. Self-monitored BG values from 8-point 24-hour profile recorded on 2 consecutive daysTime frame: Within the week prior to baseline, week 12 and week 24
  4. Episodes of hypoglycemia (symptomatic, total and categorized as day-time/nocturnal, severe or asymptomatic)Time frame: All across the study
  5. Self-monitored BG values whenever patient experiences symptoms possibly related to hypoglycemia.Time frame: All across the study

Locations

20 sites in 20 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    North Ryde, Australia

  • Sanofi-Aventis

    São Paulo, Brazil

  • Sanofi-Aventis

    Laval, Canada

  • Sanofi-Aventis

    Hoersholm, Denmark

  • Sanofi-Aventis

    Helsinki, Finland

  • Sanofi-Aventis

    Berlin, Germany

  • Sanofi-Aventis

    Mumbai, India

  • Sanofi-Aventis

    Dublin, Ireland

  • Sanofi-Aventis

    Gouda, Netherlands

  • Sanofi-Aventis

    Porto Salvo, Portugal

  • Sanofi-Aventis

    Bucharest, Romania

  • Sanofi-Aventis

    Moscow, Russia

  • Sanofi-Aventis

    Belgrade, Serbia

  • Sanofi-Aventis

    Seoul, South Korea

  • Sanofi-Aventis

    Barcelona, Spain

  • Sanofi-Aventis

    Stockholm, Sweden

  • Sanofi-Aventis

    Meyrin, Switzerland

  • Sanofi-Aventis

    Taipei, Taiwan

  • Sanofi-Aventis

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis

    Guildford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.